<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864718</url>
  </required_header>
  <id_info>
    <org_study_id>TFD-ALA</org_study_id>
    <nct_id>NCT03864718</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Anal Fistula</brief_title>
  <official_title>Efficacy of Photodynamic Therapy and Intra-lesional 5-wing in Complex Perianal Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: Validate and analyze the results of intralesional photodynamic therapy in the
      treatment of complex anal fistula.

      Methods: Prospective observational study including patients treated for complex anal fistula
      who underwent intralesional photodynamic therapy (i-PDT). Patients were included with a
      minimum follow up of 1-year, in order to evaluate recurrence, continence and postoperative
      morbidity. Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula.
      The internal and external orifices were closed. After an incubation period of 2 h, the
      fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT,
      INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Healing</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Yes/Not</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Rectal Fistula</condition>
  <arm_group>
    <arm_group_label>complex anal fistula</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
    <description>Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).</description>
    <arm_group_label>complex anal fistula</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  complex anal fistula according to Parks classification

        Exclusion Criteria:

          -  Non cryptoglandular fistulas

          -  acute sepsis

          -  inflammatory bowel diseases

          -  simple fistulas (defined as subcutaneous, intersphincteric and low transsphincteric
             fistula)

          -  pregnant patients

          -  ASA IV

          -  patients &lt;18

          -  immunocompromised

          -  patients who refused consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 3, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</investigator_affiliation>
    <investigator_full_name>Antonio Arroyo Sebastian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

